Articles related to ADJUVANT TREATMENT

In a significant shift, a new phase 3 trial suggests reconsidering adjuvant radiotherapy after radical prostatectomy, as many patients may not require it long-term, potentially reducing morbidity risks.

This prospective cohort study presents compelling evidence that omitting radiotherapy in women over 55 with specific luminal A breast cancer characteristics may lead to a low incidence of local recurrence at 5 years.

The IDEA study’s findings have led to a notable change in the treatment of stage III colon cancer, with a shift towards a 3-month duration using CAPOX. Explore the detailed analysis and its implications for your practice.

Explore the detailed findings of a recent study that highlights the impact of treatment interruptions on survival rates in triple-negative breast cancer patients undergoing adjuvant radiotherapy.

Explore the intricacies of squamous-cell carcinoma of the skin treatment, from the role of adjuvant therapy to the importance of close clinical surveillance, particularly in immunosuppressed patients.

Pivotal Role of Adjuvant Osimertinib in EGFR-Mutated NSCLC Survival A groundbreaking phase 3 trial reveals the significant impact of adjuvant osimertinib on overall survival rates in patients with resected, EGFR-mutated, stage IB to IIIA non-small-cell lung cancer (NSCLC). “Adjuvant osimertinib provided a significant overall survival benefit among patients with completely resected, EGFR-mutated, stage IB to IIIA NSCLC.” ADAURA ClinicalTrials.gov number, NCT02511106